WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--In a new post-hoc analysis presented for the first time at the American Diabetes Association (ADA) 70th Annual Scientific Sessions, significantly more patients treated with the DPP-4 inhibitor JANUVIA (sitagliptin) for one year achieved a composite endpoint of A1C1 reduction (greater than 0.5 percent), no hypoglycemia and no weight gain compared with patients treated with glipizide, a commonly used sulfonylurea.
